ArticleScientific reports2025
Risks of cataract surgery in solid and hematologic cancer survivors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In this nationwide retrospective cohort study, we investigated the risk of cataract surgery among cancer survivors compared to propensity score (PS)-matched non-cancer controls. This study included 4.5 million adults in the National Health Insurance Service database who underwent health screenings between year 2011 and 2014. PS-matching at a 3:1 ratio resulted in 167,766 non-cancer controls and 55,968 patients with cancer. During a period of up to 10 years, 7703 (13.8%) patients with cancer and 24,369 (14.5%) patients in the control group underwent cataract surgery. Survival analysis showed no difference in cataract surgery risk between the overall cancer cohort and controls. Analysis by cancer types showed that solid cancers did not increase the risk of cataract surgery compared to controls, whereas hematologic cancer survivors exhibited a significantly increased risk of cataract surgery, particularly between 2 and 5 years post-index date (hazard ratio at second year, 1.81; 95% confidence interval, 1.07-3.05; p = 0.027). Among hematologic cancer survivors, factors significantly associated with increased cataract surgery risk included advanced age, leukemia diagnosis, bone marrow transplantation, and prolonged steroid use. This study highlights the elevated risk of cataract surgery among hematologic cancer survivors, emphasizing the need for long-term ophthalmologic follow-up in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.